AFT Pharmaceuticals (ASX:AFP) downgrades earnings guidance

Company News

by Melissa Darmawan

AFT Pharmaceuticals (ASX:AFP) revised its guidance for the year following a number of Covid-19 related delays.

The company is now reporting operating profit to be between $9 -$11 million dollars compared to the $11.4 million at the same time last year.

This is due to delays in licensing negotiations and disruptions to the company’s global supply and distribution networks.

AFT expects revenue for the 2021 financial year to be around $110 million, representing an uplift on the prior year’s $105.6 million.

Shares in AFT Pharmaceuticals (ASX:AFP) are trading flat at $4.40.

Are you a 708 sophisticated investor?

A sophisticated investor is defined under Section 708 of the Corporations Act (net assets of $2.5 million or annual incomes in excess of $250,000).

They are eligible to receive information regarding wholesale investment opportunities that are not available to regular or retail investors.

Please subscribe if you would like to be alerted to these types of opportunities.